Amedisys (NASDAQ:AMED - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $1.13 per share and revenue of $597.43 million for the quarter.
Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. On average, analysts expect Amedisys to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Amedisys Stock Performance
Shares of NASDAQ:AMED traded down $0.15 during midday trading on Friday, reaching $91.76. 133,860 shares of the company traded hands, compared to its average volume of 400,397. The firm's fifty day moving average price is $92.14 and its two-hundred day moving average price is $91.86. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.41, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research note on Wednesday. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Amedisys presently has a consensus rating of "Hold" and an average target price of $100.75.
Check Out Our Latest Research Report on Amedisys
About Amedisys
(
Get Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
